

**PACKAGE LEAFLET FOR:  
ALPHA JECT micro 1 PD, Emulsion for injection, vaccine for Atlantic salmon**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

PHARMAQ AS  
Skogmo Industriområde  
Industrivegen 50  
N-7863 Overhalla, Norway

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ALPHA JECT micro 1 PD  
Emulsion for injection, vaccine for Atlantic salmon

**3. STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS**

1 dose (0.05 ml) contains:

Active substance:

Formaldehyde inactivated culture of:  
Salmon Pancreas Disease Virus (SPDV) strain AL V405 RPS<sub>end</sub><sup>a</sup> ≥ 80%

Adjuvant: Liquid paraffin  
Excipients: Sorbitan oleate, Polysorbate 80

Pharmaceutical form: Emulsion for injection  
Appearance of the product: White to cream coloured emulsion

<sup>a</sup>RPS<sub>end</sub> = Relative percentage survival at end control mortality in a laboratory test in Atlantic salmon

**4. INDICATION**

For active immunization of Atlantic salmon to reduce mortality, lesions in the heart and pancreas and impaired growth caused by Pancreas Disease (PD).

Onset of immunity occurs no later than 516 degree days after vaccination.

Duration of immunity:

The vaccine reduces mortality, development of lesions in the heart and pancreas and impaired growth caused by SPDV infection for up to at least 12 months after vaccination.

**5. CONTRAINDICATIONS**

None

**6. ADVERSE REACTIONS**

Melanisation and vaccine residues are very commonly observed in the abdominal cavity after vaccination. Mild visceral adhesions (corresponding to Spielberg scores 1 – 2) are very common, moderate adhesions (corresponding to Spielberg scores 3) are common, while the occurrence of severe adhesions (corresponding to Spielberg score  $\geq 4$ ) is very rare. The same frequencies for visceral adhesions are observed both in fresh water and in sea water.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals )
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinarian/fish health biologist.

## **7. TARGET SPECIES**

Atlantic salmon (*Salmo salar* L) with a minimum weight of 28 g.

## **8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION**

The recommended dose is 0.05 ml per fish with a minimum weight of 28 g administered by intraperitoneal injection (i.p).

The vaccine should be left to slowly reach 15-20°C by keeping it at room temperature. The vaccine should be well shaken prior to use by squeezing and shaking for approx. 2 minutes. Only administer if the vaccine appears as a homogenous, cream coloured emulsion

## **9. ADVICE ON CORRECT ADMINISTRATION**

The recommended dose is 0.05 ml per fish. The vaccine will be administered by intraperitoneal (i.p) injection. The fish should be anaesthetised prior to injection. It is recommended to starve the fish for a minimum of 48 hours before vaccination.

To reduce the risk of adverse reactions, it is important to deposit the entire dose into the abdominal cavity. The injection needle used should have appropriate length to penetrate the abdominal wall by 1-2 mm. The entire needle should be inserted into the midline about one fin length anterior to the base of the pelvic fin..

The injection devices used for vaccination, i.e. automatic vaccination machines or manual syringes, must be designed and suitable for administration of the recommended dose volume in the target species. The devices must be operated by trained personnel and should be calibrated according to the manufacturers' recommendation prior to use. Special care should be taken to ensure air is removed from the injection equipment (chambers and tubes) prior to vaccination. Regular dose controls (number of injections per bag) are recommended.

## **10. WITHDRAWAL PERIOD**

Zero degree days.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label.

Shelf life after first opening the container: 10 hours

Do not use if the vaccine shows signs of a brownish water phase in the bottom of the container before shaking. Contact the manufacturer for further advice.

## 12. SPECIAL WARNINGS

### Special precautions for use in animals:

Fish with clinical symptoms of disease should not be vaccinated. Vaccination should preferably be performed at water temperatures of 15°C or lower. Avoid vaccination during smoltification.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The use of needle guards is recommended in order to reduce the risk of accidental self-injection.

To the user:

This product contains mineral oil. Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling which may, for example, result in ischemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

### Fertility:

Vaccination of broodfish is not recommended and should be subject to a risk benefit evaluation of the prescribing veterinarian/fish health biologist.

### Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be administered with PHARMAQ's oil adjuvanted multivalent vaccines containing the following antigens: *Aeromonas salmonicida*, *Listonella anguillarum* O1 and O2a, *Vibrio salmonicida*, *Moritella viscosa* and Infectious Pancreas Necrosis Virus (IPNV). The vaccines are administered intraperitoneally either simultaneously (one injection) or in immediate succession (two injections) while fish are anaesthetised.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine

before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Do not mix with any other veterinary medicinal products.

Overdose (symptoms, emergency procedures, antidotes):

Administration of the vaccine in 0.1 ml (double dose) shows no other adverse reactions than those described in section 6.

### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Ask your veterinarian/fish health biologist how to dispose of medicines no longer required. These measures should help to protect the environment.

### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

17 December 2015

### **15. OTHER INFORMATION**

Reduction of mortality during clinical outbreaks of Pancreas Disease has been documented for up to 15 months post vaccination under field conditions.

Injection bags made of a multilayer plastic foil. The giving port is closed with a rubber stopper.  
Pack size: 250 ml and 500 ml

Not all pack sizes may be marketed.

To be supplied only on veterinary prescription  
Vm 21714/4005

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

PHARMAQ Ltd  
Unit15, Sandleheath Industrial Estate  
Fordingbridge, Hampshire SP6 1PA,  
United Kingdom

Tel.: 01425 656081, e-mail: [fordingbridge@pharmaq.no](mailto:fordingbridge@pharmaq.no)